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Abstract  
Field study to assess the concurrence of the psychopathology of drug addiction, and to evaluate the efficacy 
of pharmacological treatment versus drug-free treatments for the psychopathology of drug addiction. A total 
of 261 patients treated for drug addiction, 131 on a drug-free treatment and the remaining 130 patients 
received a drug regime, of which 113 were, according to the Prochaska and Decrement’s Transtheorical 
Model, in a initial phase of the treatment (from 15 days to 6 months of treatment) and 148 in a maintenance 
phase in drug treatment (> 6 months), were psychopathologically assessed using the SCL-90-R (Derogatis, 
2002). A field study with a 2 X 2 design (treatment: drug-free vs. drug-regime) and (treatment phase: initial 
phase vs. maintenance in drug treatment) was carried out. The results support the hypothesis of a dual 
diagnosis, that is, the comorbidity of psychopathology and drug addiction. On the whole, treatment for drug 
addiction had a significant impact on reducing associated psychopathology. Finally, the results are discussed 
in the light of the implications for the treatment of drug addiction.  
Keywords: psychopathology, drug addiction, drug-free programme, antagonists, agonists, dual diagnosis.  
Resumen  
Nos planteamos un estudio para conocer de un modo sistemático la psicopatología entre los 
drogodependientes, y contrastar la eficacia de los tratamientos farmacológicos y libres de drogas sobre la 
psicopatología de los pacientes. Para ello tomamos 261 pacientes a tratamiento de drogodependencia, 131 en 
un programa libre de drogas y 130 en tratamiento farmacológico, y, de acuerdo con el Modelo Transteórico 
de Prochaska y Diclemente, 113 en fase de acogida (de 15 días a 6 meses en el tratamiento) y 148 en fase de 
permanencia en el tratamiento (> de 6 meses de tratamiento), que fueron evaluados en la psicopatología 
mediante el SCL-90-R (Derogatis, 2002). Se planificó un estudio de campo con un diseño 2 (tratamiento: 
libre de drogas vs. tratamiento farmacológico) X 2 (tiempo de tratamiento: fase de acogida vs. fase de 
permanencia). Los resultados mostraron un apoyo a la hipótesis de un diagnóstico dual, esto es, la 
coocurrencia de patología psíquica y algún tipo de dependencia; y, en general, el tratamiento de la 
drogodependencia tiene unos efectos significativos en la reducción de la psicopatología asociada. Finalmente, 
se discuten las implicaciones de los resultados para el tratamiento de la drogodependencia.  
Palabras clave: psicopatología, drogodependencia, programa libre de drogas, antagonistas, agonistas, 
diagnóstico dual.  
Introduction  
The literature has systematically reported a co-occurrence between psychopathology and drug 
addiction (e.g., Abbot, Weller, & Walker, 1994; Cacciola et al., 2001; Fernández-Miranda et al., 
2001; Krausz, Verthein, & Degkwitz, 1999; Mateu, Astals, & Torrens, 2005). Nevertheless, there 
is no agreement as to the underlying causes i.e., whether psychopathology is the root cause of drug 
addiction (Khantzian 1985), or conversely drug addiction predisposes an individual to 
psychopathology (Arseneault et al., 2002; Rounsaville et al., 1982). Notwithstanding, the high 
incidence of comorbidity between drug addiction and psychiatric disorders has led to the coining 
of the term “dual disorder” diagnosis to refer to the coexistence of both mental health disorders. 
The prevalence of this duality is high both in psychiatric populations, ranging from 30 to 50%, and 
among drug addicts, around 80% (Rounsaville, Weisman, Kleber, & Wilbur, 1982). The simple 
observation of these rates suggest that both routes are possible and compatible; that is, there is a 
reciprocal relationship where drug addiction can give rise to a secondary psychopathology and a 
psychopathology can lead to drug abuse (Arias, Padín, & Fernández, 1997).  
 
Irrespective of the direction taken by patients to either disorder, treatment should encompass 
both afflictions i.e., addiction and psychopathology, if intervention is to be efficacious (Arce, 
Díaz, & Justo, 2003; Woody, McLellan & O’Brien, 1990), and to prevent relapse (Beleña & 
Báguena, 1993).  
 
Hence the aim of the present field study was twofold: a) to systematically map the 
epidemiology of psychopathology among drug addicts; and b) to assess the efficacy of 
pharmacological and drug-free treatments on the psychopathology of patients.  
Method  
Participants  
A total of 261 patients undergoing treatment for heroine drug abuse (though most were multi-
drug abusers) were included for study. Of these, 131 were from “Proyecto Hombre” (57 were 
undergoing rehabilitation and 74 maintenance treatment), the remaining 130 patients were from 
Units for Attending Drug Addicts (56 undergoing rehabilitation and 74 maintenance treatment). 
As for gender and age, 84.6% were men and 15.4% women, and the mean age was 22.4 years. In 
terms of marital status, 73.5% were single, (19.8%) married or living with a partner, and (6.6%) 
divorced, separated or in the process of either of the two. The average age of drug initiation for 
alcohol, hashish, and heroine was 14, 14, and 18 years, respectively.  
Procedure and design  
Patients completed a sociodemographic questionnaire (.e.g., age, gender), a questionnaire on 
the history of illicit drug abuse, criminal record, main type of illicit substance abuse, as well as 
being administered the SCL-90-R (Derogatis, 1977, 2002). Moreover, patient treatment files were 
reviewed to determine the type and duration of treatment.  
 
The research method consisted of a quasi-experimental design in a natural environment. A 2 X 
2 full factorial design with two factors (treatment type x treatment time) was used with each factor 
being applied two levels for psychopathology. The data for the treatment type factor, 
“Pharmacological Treatment” (with agonists during the rehabilitation phase and antagonists in the 
maintenance phase) vs. “Drug-Free Programme”, were provided by the treatment centres. The 
objectives of the Drug-Free Programme (DFP) were: extinction of drug-seeking behaviour, drug 
prevention in different social settings, restoring the patient’s health, and solving or minimizing 
personal conflicts, be they interpersonal or family. The first step of the programme involved 
disintoxication under either or outpatient medical care prior to gradually moving towards family, 
occupational and social integration in drug-free environments. In the long-term, following a 
number of years of permanent and complete abstinence, one may speak of recovery. As for the 
“Pharmacological Treatment” the objectives of the Methadone Maintenance Programme (MMP) 
were to: wean addicts off drugs by gradually decreasing the dosage prescribed, reduce high-risk 
behaviour or habits, raise quality of life, encourage addicts to join rehabilitation programmes, 
ensure programme compliance and maintenance of abstinence, reduce programme drop-out rates, 
reduce antisocial behaviour, and bring about changes in attitudes and behaviour.  
 
Although chemically unlike heroin or morphine, methadone is prescribed as substitution 
treatment of opioid addiction as it acts on opioid receptors and thus mimics many of the effects. 
Methadone is particularly indicated for addicts who have not responded to previous treatment, 
cases involving severe organic pathology, long-term drug abusers or for patients who are reluctant 
to undergo disintoxication. Further benefits derived from methadone treatment are a decrease in 
crime and violence resulting from the acquisition of illicit drugs, minimizing the harm of 
adulterated illicit street drugs, reducing the risk of contracting certain diseases such as HIV/AIDS 
and hepatitis as well as other diseases associated with intravenous drug usage, a fall in morbidity, 
and greater social control. Methadone therapy, however, is controversial and critics have argued it 
is simply replacing one drug addiction with another. In other words, dependency upon opioid 
substitutes is a result of failed medical interventions, and loss of professional integrity and 
ideology i.e., legitimizing and prescribing drug abuse. Nevertheless, after a six-month 
rehabilitation period using methadone treatment, some patients moved onto maintenance treatment 
i.e., the Naltrexone Maintenance Programme (NMP) based on the administration of naltrexone 
hydrochloride which is an opioid antagonist. The supervised use of this drug acts as a protective 
factor for patients and their families given that the goal is to ensure patient treatment compliance 
and retention, prevent the consumption of opioids, modify pernicious habits and restore health. 
Naltrexone is particularly indicated for patients who have previously failed to respond to DFPs.  
 
The second factor, Patient Retention on Treatment (the data were obtained from the patient 
files provided by the treatment centres), was designed to determine the effects of treatment on 
psychopathological disorders. Two levels were codified, “Rehabilitation Stage” and “Maintenance 
Stage”, according to the duration of the patient’s retention on treatment: up to 6 months for the 
Rehabilitation Stage, and more than 6 months for the Maintenance Stage. In accordance with the 
Transtheoretical Model (DiClemente & Prochaska, 1982; Prochaska & DiClemente, 1982; 
Prochaska, DiClemente, & Norcross, 1992), this factor is related to “Action” stages of change 
whereby problematic behaviour is modified over a period that spans from 15 days to 6 months of 
abstinence, followed by “Maintenance” a period of maintaining the therapeutic achievements over 
a period time which is estimated to last "from 6 months to about 5 years". 
Results and conclusions  
Study of the mental health of drug addicts.  
In relation to the symptom dimensions, patients in the Rehabilitation Stage, in comparison to 
the general population, revealed pathological indices in all of the variables assessed on the SCL-
90-R: somatisation, obsessive-compulsive disorder, interpersonal sensitivity, depression, anxiety, 
hostility, phobic anxiety, paranoia and psychoticism (see Table 1). Likewise, the global clinical 
indices portray a general pathological condition (see Table 2), which underscores the need for 
combining drug rehabilitation with clinically efficacious treatments. 
  
Table 1. T test for a sample on the SCL-90-R symptom dimensions (test value: mean of the general population). 
Variables t p MRehab MGP 
     
Somatisation  3.346 .001 .79 .55 
Obsessive-compulsive  11.151 .000 1.47 .60 
Interpersonal sensitivity  8.582 .000 1.12 .45 
Depression  8.607 .000 1.49 .72 
Anxiety  5.854 .000 .95 .52 
Hostility  7.078 .000 1.04 .45 
Phobic anxiety  5.256 .000 .52 .25 
Paranoid ideation 9.445 .000 1.24 .47 
Psychoticism  10.167 .000 .87 .21 
     
 
Note: MRehab= Mean of the drug addict group in the “Rehabilitation Stage”; MGP= Mean of the general population. 
Table 2. T test for a sample on the global indices of distress of the SCL-90-R (test value: mean of the general population). 
Variables t p MRehab MGP 
     
Global severity index  9.222 .000 1.088 .51 
Positive symptom total  10.481 .000 46.17 25.32 
Positive symptom distress index  2.019 .046 2.09 1.75 
     
 
Note: MDA= Mean of the drug addict group in the “Rehabilitation Stage”; MGP= Mean of the general population. 
Furthermore, the study of cases showed that, in comparison to psychiatric populations, subjects 
in “Rehabilitation” exhibited a high prevalence of disorders (see Table 3). The finding highlights 
that patients under treatment for drug addiction are likely to have comorbid psychiatric conditions 
(on a par with psychiatric populations) consisting of obsessive-compulsive disorder, depression, 
hostility paranoid ideation. In other words, patients undergoing drug rehabilitation, besides 
addiction exhibit psychiatric condition characterized by: a) having thoughts, feelings and 
behaviours involving irresistible or impulsive drug craving that overwhelms and self-alienates the 
individual; b) feeling of detachment or estrangement from others, lack of motivation, interest or 
pleasure in life's activities, emotional numbness, affective indifference, dysphoric emotions, 
fatigue, and even suicidal tendencies; c) aggressive thoughts, feelings and behaviour, irritability, 
bitterness, anger and rage; and d) mistrust, self-centeredness, self-referential, delirious ideation, 
hostility, grandiosity, fear of losing control and the need for control. These emotions combined 
with the effects of treatment further aggravate the psychiatric disorders e.g., obsessive–compulsive 
and depressive symptomatology but not hostility and paranoid ideation. Once again, these findings 
underscore the need for implementing integrated treatment for the management of both addictive 
behaviour and associated pathologies. 
  
Table 3. Percentage of clinical cases in the “Rehabilitation Stage” group and t test for a sample of the “Rehabilitation 
Stage” group on the SCL-90-R symptom dimensions (Test value: mean of the psychiatric population). 
Variables %cc MPP t p 
     
Somatisation  13.46 1.67 -12.23 .000 
Obsessive-compulsive 44.23 1.42 .7 .487 
Interpersonal sensitivity  14.42 1.89 -9.79 .000 
Depression  37.5 1.61 -1.27 .207 
Anxiety  20.19 1.64 -9.25 .000 
Hostility  32.69 1.18 -1.9 .092 
Phobic anxiety 13.46 1.04 -9.78 .000 
Paranoid ideation  43.26 1.33 -1.06 .291 
Psychoticism  33.65 1.03 -2.42 .017 
     
 
Note: %CC= Percentage of clinical cases in the drug addict group; MPP= Mean of the psychiatrict population. 
Analysis of the effects of the treatment in the psychopathology.  
Significant multivariate differences were found for psychopathology as measured by the factor 
“treatment time” (“Rehabilitation Stage” versus “Maintenance Stage), Fmultivariate (9,247)= 4.011; 
p< .01; η2= .128. Thus, the stabilization of drug addiction treatment had effects on 
psychopathology and explained 12.8% of it. 
 
As for the univariate effects (see Table 4), patients in “Rehabilitation Stage” presented more 
symptomatology “obsessive–compulsive”, “depressive” and “psychotic” than those in the 
Maintenance Stage. In other words, patients in the “Rehabilitation Stage” had more thoughts, 
feelings and behaviours involving irresistible or impulsive drug craving that overwhelm and self-
alienate the individual e.g., symptomatology of repetitive unpleasant thoughts that one cannot get 
rid off, feeling of being powerless or incapable of doing things; difficulty in remembering things; 
worried about tidiness and neglected appearances; obsessive thoughts; impaired mental capacity or 
function. Moreover, patients in the “Rehabilitation Stage” exhibited more depressive symptoms 
than patients Maintenance Stage i.e., feeling of detachment or estrangement from others, lack of 
motivation, interest or pleasure in life's activities, emotional numbness, affective indifference, 
dysphoric emotions, fatigue, and even suicidal tendencies. Examples of this symptoatology are: 
lack of sexual appetite, feelings of loneliness, crying, sadness or lack of energy. Finally, patients in 
the “Rehabilitation Stage” had more psychotic pathologies than those on maintenance treatment 
i.e., isolation, schizoid way of life, social introversion, hallucinations and disordered thoughts 
which are linked to a negative self-evaluation confounded by a sense of personal 
underachievement. Examples of psychotic symptomatology were: the belief that someone was 
controlling their thoughts; hearing voices that others did not hear; feeling distant to other people; 
feeling lonely even in the company of other people. Hence, the data lend support to our hypothesis 
that treatment for drug addiction reduces concomitant psychopathological disorders. In addition, 
this hypothesis has two further considerations. First, drug addiction produces psychic as well as 
social and personal injury, which runs counter to the claim that psychological disorders induce 
drug addiction. Second, traditional drug addiction treatments as well as the evaluation of drug 
addicts must be combined with specific diagnosis and treatment of associated pathologies. In our 
study subjects beginning rehabilitation treatment exhibited a significant comorbid clinical 
condition in practically all of the clinical indices but did not receive combined treatment. 
  
Table 4. Univariate effects in psychopathology by the en la patología terciados por el factor “permanencia en el 
tratamiento” 
Variable SS F p ƞ MRehab MMain 
       
Somatisation  .558 1.064 .303 .004 .775 .871 
Obsessive-compulsive  4.541 6.595 .011 .025 1.472 1.2 
Interpersonal sensitivity  .320 .561 .455 .002 1.124 1.052 
Depression  4.327 6.142 .014 .024 1.468 1.202 
Anxiety  .0045 .008 .928 .000 .931 .923 
Hostility  1,560 2.515 .114 .010 1.023 .864 
Phobic anxiety  .07469 .205 .651 .001 .524 .559 
Paranoid ideation  .310 .263 .609 .001 1.232 1.303 
Psychoticism  2.060 4.667 .032 .018 .871 .688 
       
 
Note: df(1,255). MRehab= Mean of the “Rehabilitation Stage” group; MMain= Mean of the “Maintenance Stage” group. 
Likewise, the 2 X 2 MANOVA showed a multivariate significant effect for psychopathology 
explained by the factor “type of treatment” (“Drug Free Programme” vs. “Drug Treatment”), 
Fmultivariate (9,247)= 2.167; p< .05; η2= .073. Nonetheless, no univariate differences were 
observed in the different variables constituting psychopathology (see Table 5). 
Table 5. Univariate effects on the psychopathology by the factor “type of treatment” (“Drug Free Programme” vs. 
“Pharmacological Treatment”) 
Variable SS F p ƞ MDFP MPT 
       
Somatisation  .519 .990 .321 .004 .869 .777 
Obsessive-compulsive  1.782 2.589 .109 .010 1.421 1.251 
Interpersonal sensitivity  .420 .736 .392 .003 1.046 1.251 
Depression  .190 .269 .392 .003 1.363 1.307 
Anxiety  .076 .140 .709 .001 .944 .909 
Hostility  1.560 2.515 .727 .000 .961 .926 
Phobic anxiety  .354 .974 .325 .004 .579 .503 
Paranoid ideation  .0066 ,006 .941 .000 1.262 1.272 
Psychoticism  1.391 3.151 .077 .012 .705 .855 
       
 
Note: df(1,255). MDFP= Mean of “Drug-Free Programme” group; MPT= Mean of “Pharmacological Treatment” group. 
In relation to the interaction between “type of treatment” and “treatment time”, the MANOVA 
revealed significant multivariate differences, Fmultivariate (9,247)= 3.012; p< .01; η
2
= .099. The 
univariate effects (see Table 6) revealed a significant interaction of the variables “somatisation” 
and “anxiety”. Succinctly, patients under “Drug Treatment” had reduced somatisation effects 
during treatment maintenance i.e., naltrexone acted as a somatisation control agent whereas 
patients on the Drugs Free programme had increased somatisation during treatment maintenance. 
The same pattern was observed for the variable anxiety i.e., greater levels of anxiety for Drug Free 
Treatment patients than “Drug Treated” patients during the maintenance stage (i.e., Methadone 
followed by Naltrexone). Thus, “Drug Treatment” was observed to reduce associated 
psychopathology whereas Drug Free Treatment was found to favour psychopathological 
manifestations. 
  
Table 6. Univariate effects for the interaction between the type of treatment” and “treatment time” factors. 
Variable SS F p ƞ  MRehab MMain 
        
Somatisation  3.784 7.222 .008 .028 MDFP .697 1.041 
     MPT .854 .701 
Obsessive-compulsive .797 1.158 .283 .005 MDFP 1.500 1.342 
     MPT 1.444 1.058 
Interpersonal sensitivity .608 1.065 .303 .004 MDFP 1.132 .061 
     MPT 1.115 1.143 
Depression 1.739 2.469 .117 .010 MDFP 1.411 1.314 
     MPT 1.524 1.091 
Anxiety 3.001 2.469 .020 .010 MDFP .838 1.051 
     MPT 1.024 .795 
Hostility .775 1.250 .265 .005 MDFP .985 .938 
     MPT 1.062 .790 
Phobic anxiety .296 .814 .368 .003 MDFP .597 .562 
     MPT .451 .556 
Paranoid ideation 2.297 1.949 .164 .008 MDFP 1.130 1.394 
     MPT 1.334 1.211 
Psychoticism .0166 .038 .846 .000 MDFP .804 .605 
     MPT .938 .772 
        
 
Note: df(1,255). MRehab= Mean of the group in the “Rehabilitation Stage”; MMain= Mean of the “Maintenance Stage” group; 
MDFP= Mean of the “Drug Free Programme” group; MPT= Mean of the “Pharmacological Treatment” group. 
Discussion  
Caution should be exercised in the interpretation of the results of this study prior to attempting 
to extrapolate or generalize them to other populations. We may identify at least three limitations 
regarding the validity of our results. First, the data obtained for the “Drug Free Programme” does 
not correspond with the heterogeneous treatments administered in other centres in Spain (e.g., 
Reto, Amanecer, Renacer, UADs). Second, the measurement instruments used restrict the results 
to the variables assessed thus the comparison with other studies is limited and the results obtained 
with these instruments cannot be generalized to other samples or contexts. Thirdly, the 
measurement technique was based on self-reports that are well known to lend themselves to data 
distortion (e.g., social desirability) which may be further amplified by the particular characteristics 
of the population under study. Bearing in mind the aforementioned limitations, we may conclude 
that:  
 
a) The comparison of the clinical condition of patients undergoing treatment for drug addiction 
with that of the general or psychiatric populations corroborates the hypothesis of a dual 
diagnosis (calculated to be in the range of 80% among substance abusers) i.e., the co-
occurrence of drug addiction and psychopathology (Khantzian & Treece, 1985; Rounsaville 
et al., 1982). Moreover, though the prevalence of different types of psychopathologies tend 
to vary according factors such as the type of substance abused, gender, and socioeconomic 
status, opiate addicts have the highest rates of comorbidity (Blaszczynski, Steel, & 
McConaghy, 1997; Calsyn, Fleming, Wells, & Saxon, 1996; Goldstein, 1995;- Gutiérrez et 
al., 1998; Miller, 1995, 1996; Sánchez-Hervás, Gradoli, & Morales, 2001; San Narciso et 
al., 1998; Sánchez-Hervás, Tomás, & Climent, 1999; Wojnar et al., 1997). In this study the 
clinical profile of the patients was assessed in relation to the following variables: 
somatisation, obsessive-compulsive disorder, interpersonal sensitivity, depression, anxiety, 
hostility, phobic anxiety, paranoia and psychoticism. Hence, as drug addicts exhibit a 
varied symptomatology, further research is required to determine the variables that may 
establish the differential clinical outcomes. Furthermore, the prevalence of severe 
pathologies (i.e., levels similar to psychiatric populations), has been related to antisocial 
behaviour (e.g., Chen et al., 1999) psychoticism (e.g., Brooner et al., 1997), anxiety (Darke 
& Roos, 1997) depression (Regier et al., 1990), and in our study to obsessive-compulsive 
disorders, depression, hostility, and paranoia.  
 
b) From the perspective of clinical treatment, the association between drugs and 
psychopathology implies a poorer prognosis: greater number of relapses, increase in the 
number hospital admittances, greater risk of suicide, violence, difficulties with employment 
and social relationships, and higher rates of HIV infection (Arias, Padín, & Fernández, 
1997; Brooner et al., 1997; Cacciola et al., 1996; Drake et al., 1989; Gerstley et al., 1990; 
Kosten et al., 1989; McLellan, 1986; Ravndal & Vaglum, 1991). Bearing in mind that 
patients undergoing treatment for drug addiction also experience associated 
psychopathologies, one would expect that rehabilitation would clearly aid the improvement 
of psychopathological conditions if management of both pathologies involves combined 
treatment (Woody, McLellan, & O’Brien, 1990). Our results reveal that treatment, in 
general, had indirect effects on psychopathology (it should be noted that they were not the 
direct or overt objectives of treatment) by contributing to the improvement of the 
individual’s clinical condition, particularly in relation to symptomatology associated to 
obsessive-compulsive disorder, depression and psychoticism. This finding may be 
explained in terms of two hypothesis that are not mutually exclusive but rather 
complementary: most treatment drop-outs had high levels of psychopathology, primarily 
psychotics (Meyer, 1986), or due to the positive effects of rehabilitation treatment itself 
(Rounsaville & Kleber, 1986). Notwithstanding, the effects vary according to the treatment 
applied i.e., the psychopathological condition of “DFP” patients is less severe than those on 
“Drug Treatment”, and during the course of treatment their clinical disorders surface, in 
particular anxiety and somatisation. Deductively, “DFP” patients are in a better clinical 
condition which may be due either to the program selection process or as a result of 
patient’s positive willingness and own personal choice. Nevertheless, this finding does not 
necessarily entail a real improvement in the clinical condition of patients undergoing 
treatment with antagonists and agonists as it is well known that they disguise clinically 
significant symptomatology (Casas, 1995; Casas et al., 1992). Thus, the results, regardless 
of the effects of treatment type and its interaction with programme retention, clearly 
underscore the need for integrated treatment programmes combining treatment for both 
drug addiction and clinical pathologies, be these intrinsic to the patient or generated by 
drug addiction. Otherwise, and in line with the Transtheoretical Change model 
(DiClemente & Prochaska, 1982; Prochaska & DiClemente, 1982; Prochaska, DiClemente, 
& Norcross, 1992), the probability of relapse will be greater.  
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